Evolution of the Patient's Perception of the Use of the Upper Limb After a Stroke During Intensive Rehabilitation (ValetM-2024)

This study is being carried out in the context of rehabilitation after stroke, where persistent upper limb weakness is a major challenge. It aims to explore the relationship between observed function and patients' perceived participation in use.

Study Overview

• Status: Recruiting
• Conditions: Upper Limb Ischemia
• Intervention / Treatment: Diagnostic test: Functional assessments

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Maxime VALET, MD; Phone Number: 119424 0032 60; Email: Maxime.VALET@ghdc.be

Study Locations

• Belgium
  • Hainaut
    • Charleroi, Hainaut, Belgium, 6060
      • Recruiting
      • Grand Hôpital de Charleroi
      • Contact: Maxime VALET, MSc; Phone Number: 119424 0032 60; Email: maxime.valet@ghdc.be
    • Mons, Hainaut, Belgium, 7000
      • Recruiting
      • CHU HELORA site Kennedy
      • Contact: Benjamin BOLLENS, MD; Email: benjamin.bollens@helora.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients who have suffered a first stroke will be selected on transfer to a neurological rehabilitation service. They will be recruited on admission, provided they meet the inclusion and exclusion criteria.

A combination of self-administered questionnaires and functional assessments will be carried out on the first day of multidisciplinary management in the neurological rehabilitation department and after two months in hospital.

Description

Inclusion Criteria:

• First stroke as defined by the World Health Organization.
• Upper limb paresis with a NIHSS National Institutes of Health Stroke Scale score > or = 1/4 for upper limb motor function

Exclusion Criteria:

• Life expectancy <12 months
• Inability to understand French.
• Pre-existing severe multiple disability affecting arm function.
• Presence of pre-existing central neurological pathologies.
• Mini-Mental State Examination < 21

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients suffering from motor impairment of the upper limbs following a stroke; Voluntary patients suffering from motor impairment of the upper limbs following a stroke	Diagnostic test: Functional assessments; Computer Adaptive Test for Fugl-Meyer (CAT-FM); Action Research Arm Test (ARAT); Measurement of Functional Independence; Star cancellation test; Stroke Impact Scale; ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess whether the perception of use of the impaired upper limb improves during intensive rehabilitation after a stroke.	various tests : computer adaptive test F-M, ARA test, MIF test, star concellation test, ACTIVLIM test	Up to 2 months
To compare the difference between perception and observed function of the upper limb during intensive multidisciplinary rehabilitation treatment.	various tests : computer adaptive test F-M, ARA test, MIF test, star concellation test, ACTIVLIM test	Up to 2 months

Collaborators and Investigators

• Sponsor: Grand Hôpital de Charleroi
• Investigators: Principal Investigator: Maxime Valet, MD, Grand Hôpital de Charleroi

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2024
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: August 19, 2024
• First Submitted That Met QC Criteria: August 21, 2024
• First Posted (Actual): August 26, 2024

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 8, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Ischemia
• Other Study ID Numbers: Perception Valet M 2024

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No